Literature DB >> 26176268

Epidermal growth factor receptor-targeted peptide conjugated phospholipid micelles for doxorubicin delivery.

Mingliang Fan1, Xiaofei Liang1, Danbo Yang1, Xiaorong Pan1, Zonghai Li1, Hongyang Wang1, Bizhi Shi1.   

Abstract

Specific targeting of tumor cells to achieve higher drug levels in tumor tissue and to overcome side effects is the major goal in cancer chemotherapy. In this study, we used a tumor targeting peptide, GE11, to conjugate onto the surface of doxorubicin encapsulated phospholipid micelles. The GE11 peptide triggered specific binding to epidermal growth factor receptor (EGFR), leading to enhanced cellular uptake and cytotoxicity in vitro and highly accumulation in the tumors in vivo. The results indicated that GE11 conjugated phospholipid micelles should have potential applications in cancer therapy.

Entities:  

Keywords:  Doxorubicin; GE11; epidermal growth factor receptor; micelles; targeted drug delivery

Mesh:

Substances:

Year:  2015        PMID: 26176268     DOI: 10.3109/1061186X.2015.1058800

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  3 in total

1.  EGFR-targeting peptide-coupled platinum(IV) complexes.

Authors:  Josef Mayr; Sonja Hager; Bettina Koblmüller; Matthias H M Klose; Katharina Holste; Britta Fischer; Karla Pelivan; Walter Berger; Petra Heffeter; Christian R Kowol; Bernhard K Keppler
Journal:  J Biol Inorg Chem       Date:  2017-04-12       Impact factor: 3.358

2.  Legomedicine-A Versatile Chemo-Enzymatic Approach for the Preparation of Targeted Dual-Labeled Llama Antibody-Nanoparticle Conjugates.

Authors:  Sanne A M van Lith; Sander M J van Duijnhoven; Anna C Navis; William P J Leenders; Edward Dolk; Jos W H Wennink; Cornelus F van Nostrum; Jan C M van Hest
Journal:  Bioconjug Chem       Date:  2017-01-18       Impact factor: 4.774

Review 3.  Phage display screening of therapeutic peptide for cancer targeting and therapy.

Authors:  Phei Er Saw; Er-Wei Song
Journal:  Protein Cell       Date:  2019-05-28       Impact factor: 14.870

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.